Eli Lilly and Company remains a Buy, supported by robust incretin-driven growth and strategic expansion in obesity treatments. LLY pivots from scarcity to access economics, prioritizing volume over ...

This is read by an automated voice. Please report any issues or inconsistencies here. Evangeline Lilly says much of her brain is “functioning at a decreased capacity” after her traumatic brain injury ...

Evangeline Lilly is sharing an update on her health following an unfortunate accident in May 2025. In an Instagram video posted on Friday, Jan. 2, the 46-year-old "Lost" star shared that she has ...

Months after sharing that she fell face-first into a boulder, Evangeline Lilly revealed she also suffered brain damage in the incident. “Verdict’s in… I do have brain damage from my (traumatic brain ...

Evangeline Lilly revealed that medical tests showed she suffered brain damage following a nasty fall onto a boulder that the Lost actress endured last year. In May, Lilly wrote that she “fainted at ...

Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. Furthermore, Novo Nordisk is anticipating ...

India's obesity drug market expected to exceed $1 billion in two years, analyst says Lilly's Mounjaro leads in sales, Novo cuts prices to compete Lilly and Novo partner with local firms to expand ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...

One of Eli Lilly’s most promising new obesity drugs helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis. The drug giant’s LLY stock was ...

Patients on Eli Lilly’s next-generation obesity shot lost nearly 30% of their body weight on average in a trial that tracked them for a little more than a year—a result that’s far better than the most ...

A next-generation obesity shot from Eli Lilly & Co. helped patients lose almost a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. The ...